OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II
2020.May.29
未分類
Corporate
OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424
2020.May.20
未分類
Corporate
OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424
2020.Apr.08
未分類
Corporate
OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic
2020.Jan.21
未分類
Corporate
OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
2020.Jan.09
未分類
Corporate
OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference
2019.Dec.26
未分類
Corporate
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
2019.Dec.19
未分類
Corporate
OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.
2019.Sep.03
未分類
Corporate
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
2019.Mar.28
未分類
Corporate
OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999
